Edge Therapeutics Announces New Data Highlighting the Potential Pharmacoeconomic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage • Reduced length of ICU stay by 3.5 days, hospital stay by 2.5 days versus standard of care • Builds on efficacy data from Phase...
Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children Safe and well tolerated over two years Height velocity (HV) in second year comparable to published US rhGH daily dosing data; further confirms Phase 3...
AiCure’s Artificial Intelligence Platform Draws $12.25 Million Series A (New York, NY) – January 11, 2016 – AiCure, an artificial intelligence company connecting the world’s patients to better treatments and improved health, has closed a Series...
Principia Biopharm advances BTK inhibitor program in autoimmune disease and FGFR inhibitor program in oncology Initiates Phase 2 clinical trial of BTK inhibitor PRN1008 in orphan autoimmune disease Advances Phase 1 clinical trial of FGFR1-4 inhibitor PRN1371 in solid...
Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B Receives Positive Opinion on European Orphan Drug Designation CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc....
Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company...
Recent Comments